The logics of leukocytapheresis as a natural biological therapy for inflammatory bowel disease

Bibliography

• ALLISON MC, DHILLON AP, LEWIS WG, POUNDER RE: Inflammatory Bowel Disease. Allison MC, Dhillon AP, Lewis WG, Pounder RE (Eds), Mosby, London, UK (1998):9-95.
   Google Scholar
• FIOCCHI C: Inflammatory bowel disease: etiology and pathogenesis. Gastroenterology (1998) 115:182-205.
   PubMed Web of Science ®Google Scholar
• PODOLSKY DK: Inflammatory bowel disease. N. Engl. J. Med. (2002) 347:417-429
   PubMed Web of Science ®Google Scholar
• HARRIS ML, BAYLESS TM: Dietary antigens as aggravating factors in Crohn’s disease. Dig. Dis. Sci. (1989) 34:1613-1614.
   PubMed Web of Science ®Google Scholar
• SHANAHAN F: Crohn’s disease. Lancet (2002) 359:62-69.
   PubMed Web of Science ®Google Scholar
• SARTOR RB: Pathogenesis and immune mechanisms of chronic inflammatory bowel diseases. Am. J. Gastroenterol. (1997) 92(Suppl.):5S-11S.
   PubMed Web of Science ®Google Scholar
• TAFFET SL, DAS KM: Sulphasalazine-adverse effects and desensitization. Dig. Dis. Sci. (1983) 28:833-842.
   PubMed Web of Science ®Google Scholar
• PRESENT DH: How to do without steroids in inflammatory bowel disease. Inflamm. Bowel Dis. (2000) 6:48-57.
   PubMed Web of Science ®Google Scholar
• RACHMILEWITZ D: Coated mesalazine (5-aminosalicylic acid) versus sulphasalazine in the treatment of active ulcerative colitis. (On behalf of an international study group). Br. Med. J. (1989) 298:82-86.
   PubMed Web of Science ®Google Scholar
• KORNBLUTH A, MARION JF, SALOMON P, JANOWITZ HD: How effective is current medical therapy for severe ulcerative colitis? J. Clin. Gastroenterol. (1995) 20:280-284.
   PubMed Web of Science ®Google Scholar
• TRUELOVE SC, JEWELL DP: Intensive intravenous regimens for severe attacks of ulcerative colitis. Lancet (1974) 1:1067-1070.
   PubMed Web of Science ®Google Scholar
• JARNEROT G, ROLNY P, SANDBERG-GERTZEN H: Intensive intravenous treatment of ulcerative colitis. Gastroenterology (1985) 89:1005-1013.
   PubMed Web of Science ®Google Scholar
• HANAUER SB: Medical therapy of ulcerative colitis. Gastroenterology (2004) 126:1582-1592.
   PubMed Web of Science ®Google Scholar
• O’KEEFE SJ: Nutrition and gastrointestinal disease. Scand. J. Gastroenterol. (1996) 220(Suppl.):52-59.
   Google Scholar
• HYDE GM, THILLAINAYAGAM AV, JEWELL DP: Intravenous cyclosporin as rescue therapy in severe ulcerative colitis: time for a reappraisal? Eur. J. Gastroenterol. Hepatol. (1998) 10:411-413.
   PubMed Web of Science ®Google Scholar
• HANAUER SB: Can cyclosporine go it alone in severe ulcerative colitis. Curr. Gastroenterol. Rep. (2001) 3:455-456.
   PubMedGoogle Scholar
• SERKOVA NJ, CHRISTIANS U, BENET LZ: Biochemical mechanisms of cyclosporine neurotoxicity. Mol. Interv. (2004) 4:97-107.
   PubMed Web of Science ®Google Scholar
• SCHREAIBER S, NIKOLAUS S, HAMPE J et al.: Tumour necrosis factor alpha and interleukin 1beta in relapse of Crohn’s disease. Lancet (1999) 353:459-461.
   PubMed Web of Science ®Google Scholar
• PAPADAKIS KA, TARGAN SR: Role of cytokines in the pathogenesis of inflammatory bowel disease. Annu. Rev. Med. (2000) 51:289-298.
   PubMed Web of Science ®Google Scholar
• TARGAN SR, HANAUER SB, VAN DEVENTER SJ: A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn’s disease. Crohn’s Disease cA2 Study Group. N. Engl. J. Med. (1997) 337:1029-1035.
   PubMed Web of Science ®Google Scholar
• HANAUER SB, FEAGAN BG, LICHTENSTEIN GR: Maintenance infliximab for Crohn’s disease: the ACCENT I randomised trial. Lancet (2002) 359:1541-1549.
   PubMed Web of Science ®Google Scholar
• RUTGEERTS P, SANDBORN WJ, FEAGAN BG et al.: Infliximab for induction and maintenance therapy for ulcerative colitis.N. Engl. J. Med.. (2005) 353:2462-2476.
   PubMed Web of Science ®Google Scholar
• KORZENIK JR, PODOLSKY DK: Evolving knowledge and therapy of inflammatory bowel disease. Nat. Rev. Drug Discov. (2006) 5:197-209.
   PubMed Web of Science ®Google Scholar
• EVANS RC, CLARKE L, HEATH P, STEPHENS S, MORRIS AI, RHODES JM: Treatment of ulcerative colitis with an engineered human anti-TNF-alpha antibody CDP571. Aliment. Pharmacol. Ther. (1997) 11:1031-1035.
   PubMed Web of Science ®Google Scholar
• IYER S, KONTOYIANNIS D, CHEVRIER D et al.: Inhibition of tumor necrosis factor mRNA translation by a rationally designed immunomodulatory peptide. J. Biol. Chem. (2000) 275:17051-17057.
   PubMed Web of Science ®Google Scholar
• TRAVIS S, YAP L, HAWKEY CJ: Novel and effective therapy for ulcerative colitis: results of parallel, prospective, placebo-controlled trials (abstr). Am. J. Gastroenterol. (2003) 98:S239.
   Google Scholar
• GORDON FH, HAMILTON MI, DONOGHUE S et al.: A pilot study of treatment of active ulcerative colitis with natalizumab, a humanized monoclonal antibody to alpha-4 integrin. Aliment. Pharmacol. Ther. (2002) 16:699-705.
   PubMed Web of Science ®Google Scholar
• FEAGAN B, GREENBERG GR, WILD G: A randomized controlled trial of a humanized alpha4beta7 antibody in ulcerative colitis (abstr). Am. J. Gastroenterol. (2003) 98:S248-S249.
   Google Scholar
• SANDBORN WJ, COLOMBEL JF, ENNS R, FEAGAN BG, HANAUER SB: Natalizumab induction and maintenance therapy for Crohn’s disease. N. Engl. J. Med. (2005) 353:1912-1925.
   PubMed Web of Science ®Google Scholar
• VAN ASSCHE G, DALLE I, NOMAN M et al.: A pilot study on the use of the humanized anti-interleukin-2 receptor antibody daclizumab in active ulcerative colitis. Am. J. Gastroenterol. (2003) 98:369-376.
   PubMed Web of Science ®Google Scholar
• TILG H, VOGELSANG H, LUDWICZEK O: A randomized placebo-controlled trial of pegylated interferon alpha in active ulcerative colitis (abstr). Gastroenterology (2003) 124:A62.
   Google Scholar
• BECK PL, PODOLSKY DK: Growth factors in inflammatory bowel disease. Inflamm. Bowel Dis. (1999) 5:44-60.
   PubMed Web of Science ®Google Scholar
• SANDBORN WJ, SANDS BE, WOLF DC et al.: Repifermin (keratinocyte growth factor-2) for the treatment of active ulcerative colitis: a randomized, double-blind, placebo-controlled, dose-escalation trial. Aliment. Pharmacol. Ther. (2003) 17:1355-1364.
   PubMed Web of Science ®Google Scholar
• DEVOS SA, VAN DEN BOSSCHE N, DE VOS M, NAEYAERT JM: Adverse skin reactions to anti-TNF-α. Dermatology (2003) 206:388-390.
   PubMed Web of Science ®Google Scholar
• SEEGERS D, BOUMA G, PENA AS: Review article: a critical approach to new forms of treatment of Crohn’s disease and ulcerative colitis. Aliment. Pharmacol. Ther. (2002) 16(Suppl. 4):53-58.
   Google Scholar
• GOMEZ-REINO JJ, CARMONA L, VALVERDE VR, MOLA EM, MONTERO MD: Treatment of rheumatoid arthritis with tumor necrosis factor inhibitors may predispose to significant increase in tuberculosis risk: a multicenter active-surveillance report. BIOBADASER Group. Arthritis Rheum. (2003) 48:2122-2127.
   PubMed Web of Science ®Google Scholar
• KROESEN S, WIDMER AF, TYNDALL A, HASLER P: Serious bacterial infections in patients with rheumatoid arthritis under anti-TNF-alpha therapy. Rheumatology (2003) 42:617-621.
   PubMed Web of Science ®Google Scholar
• BROWN SL, GREENE MH, GERSHON SK, EDWARDS ET, BRAUN MM: Tumor necrosis factor antagonist therapy and lymphoma development: twenty-six cases reported to the Food and Drug Administration. Arthritis Rheum. (2002) 46:3151-3158.
   PubMed Web of Science ®Google Scholar
• ATZENI A, ARDIZZONE S, SARZI-PUTTINI P et al.: Autoantibody profile during short-term infliximab treatment for Crohn’s disease: a prospective cohort study. Aliment. Pharmacol. Ther. (2005) 22:453-461.
   PubMed Web of Science ®Google Scholar
• TIBBLE JA, SIGTHORSSON G, BRIDGER D, FAGERHOL MK, BJARNASON I: Surrogate markers of intestinal inflammation are predictive of relapse in patients with inflammatory bowel disease. Gastroenterology (2000) 119:15-22.
   PubMed Web of Science ®Google Scholar
• LIMBURG P, DAVID M, AHLQUIST A, SANDBORN WJ: Faecal calprotectin levels predict colorectal inflammation among patients with chronic diarrhoea referred for colonoscopy. Am. J. Gastroenterol. (2000) 95:2831-2837.
   PubMed Web of Science ®Google Scholar
• ROSETH AG, SCHMIDT PN, FAGERHOL MK: Correlation between faecal excretion of Indium-111-labelled granulocytes and calprotectin, a granulocyte marker. Scand. J. Gastroenterol. (1999) 34:50-54.
   PubMed Web of Science ®Google Scholar
• CASSATELLA MA: The production of cytokines by polymorphonuclear neutrophils. Immunol. Today (1995) 16:21-26.
   PubMedGoogle Scholar
• NIKOLAUS S, BAUDITZ J, GIONCHETTI P: Increased secretion of pro-inflammatory cytokines by circulating polymorphonuclear neutrophils and regulation by interleukin-10 during intestinal inflammation. Gut (1998) 42:470-476.
   PubMed Web of Science ®Google Scholar
• MCCARTHY DA, RAMPTON DS, LIU YC: Peripheral blood neutrophils in inflammatory bowel disease: morphological evidence of in vivo activation in active disease. Clin. Exp. Immunol. (1991) 86:489-493.
   PubMed Web of Science ®Google Scholar
• MAHIDA YR: The key role of macrophages in the immunopathogenesis of inflammatory bowel disease. Inflamm. Bowel Dis. (2000) 6:21-33.
   PubMed Web of Science ®Google Scholar
• HANAI H, WATANABE F, SANIABADI A, MATSUSHITA I, TAKEUCHI K, IIDA T: Therapeutic efficacy of granulocyte and monocyte adsorption apheresis in severe active ulcerative colitis. Dig. Dis. Sci. (2002) 47:2349-2353.
   PubMed Web of Science ®Google Scholar
• HANAI H, WATANABE F, TAKEUCHI K, SANIABADI A, BJARNASON I: Leukcocyte adsorptive apheresis for the treatment of active ulcerative colitis: a prospective uncontrolled pilot study. Clin. Gastroenterol. Hepatol. (2003) 1:28-35.
   PubMed Web of Science ®Google Scholar
• SANIABADI AR, HANAI H, BJARNASON I, LOFBERG R: Adacolumn, an adsorptive carrier based granulocyte and monocyte apheresis device for the treatment of inflammatory and refractory diseases associated with leukocytes. Ther. Apher. Dial. (2003) 7:48-59.
   PubMed Web of Science ®Google Scholar
• RUGTVEIT J, BRANDTZAEG P, HALSTENSEN TS, FAUSA O, SCOTT H: Increased macrophage subsets in inflammatory bowel disease: apparent recruitment from peripheral blood monocytes. Gut (1994) 35:669-674.
   PubMed Web of Science ®Google Scholar
• MEURET G, BITZI A, HAMMER B: Macrophage turnover in Crohn’s disease and ulcerative colitis. Gastroenterology (1978) 74:501-503.
   PubMed Web of Science ®Google Scholar
• BRANNIGAN AE, O’CONNELL PR, HURLEY H: Neutrophil apoptosis is delayed in patients with inflammatory bowel disease. Shock (2000) 13:361-366.
   PubMed Web of Science ®Google Scholar
• MEAGHER LC, COUSIN JM, SECKL JR, HASLETT C: Opposing effects of glucocorticoids on the rate of appoptosis in neutrophilic and eosinophilic granulocytes. J. Immunol. (1996) 156:4422-4428.
   PubMed Web of Science ®Google Scholar
• GRISHAM MB, YAMADA T: Neutrophils, nitrogen oxides and inflammatory bowel disease, neuro-immuno-physiology of the gastrointertinal mucosa. Ann. NY Acad. Sci. (1992) 664:103-115.
   PubMed Web of Science ®Google Scholar
• MORSE EE, CARBONE PP, FREIREICH EJ, BRONSON W, KLIMAN A: Repeated leukapheresis of patients with chronic myelocytic leukemia. Transfusion (1966) 6:175-182.
   Web of Science ®Google Scholar
• BUCKNER D, GRAW RG JR, EISEL RJ, HENDERSON ES, PERRY S: Leukapheresis by continous flow centrifugation (CFC) in patients with chronic myelocytic leukemia (CML). Blood (1969) 33:353-369.
   PubMed Web of Science ®Google Scholar
• CURTIS JE, HERSH EM, FREIREICH EJ: Leukoapheresis therapy of chronic lymphocytic leukemia. Blood (1972) 39:163-175.
   PubMed Web of Science ®Google Scholar
• PEARSON CM, PAULUS HE, MACHLEDER HI: The role of the lymphocyte and its products in the propagation of joint disease. Ann. NY Acad. Sci. (1975) 256:150-168.
   PubMed Web of Science ®Google Scholar
• TENENBAUM J, UROWITZ MB, KEYSTONE EC, DWOSH IL, CURTIS JE: Leukoapheresis in severe rheumatoid arthritis. Ann. Rheum. Dis. (1979) 38:40-44.
   PubMed Web of Science ®Google Scholar
• BICKS RO, GROSHART KW, CHANDLER RW: The treatment of severe chronically active Crohn’s disease by T8 (suppressor cell) lymphapheresis (Abstr). Gastroenterology (1985) 88:A1325.
   Google Scholar
• BICKS RO, GROSHART KW, CHANDLER RW: The treatment of severe chronically active Crohn’s disease by T lymphocyte apheresis (Abstr). Gastroenterology (1986) 90:A1346.
   Google Scholar
• BICKS RO, GROSHART KW, LUTHER RW: Total parenteral nutrition (TPN) plus T-lymphocyte apheresis (TLA) in the treatment of severe chronic active Crohn’s disease (Abstr). Gastroenterology (1987) 94:A34.
   Google Scholar
• LEREBOURS E, BUSSEL A, MODIGLIANI R et al.: Treatment of Crohn's disease by lymphocyte apheresis: a randomized controlled trial. Groupe d'Etudes Therapeutiques des Affections Inflammatoires Digestives. Gastroenterology (1994) 107:357-361.
   PubMed Web of Science ®Google Scholar
• AYABE T, ASHIDA T, TANIGUCHI M et al.: A pilot study of centrifugal leukocyte apheresis for corticosteroid-resistant active ulcerative colitis. Intern. Med. (1997) 36:322-326.
   PubMed Web of Science ®Google Scholar
• AYABE T, ASHIDA T, KOHGO Y: Centrifugal leukocyte apheresis for ulcerative colitis. Ther. Apher. (1998) 2:125-128.
   PubMedGoogle Scholar
• KOHGO Y, HIBI T, CHIBA T et al.: Leukocyte apheresis using a centrifugal cell separator in refractory ulcerative colitis; a multicenter open label trial. Study group for Alternative Therapies in Ulcerative Colitis Patients. Ther. Apher. (2002) 6:255-260.
   PubMedGoogle Scholar
• HIRAISHI K, TAKEDA Y, SANIABADI A et al.: Studies on the mechanisms of leukocyte adhesion to cellulose acetate beads: an in vitro model to assess the efficacy of cellulose acetate carrier-based granulocyte and monocyte adsorptive apheresis. Ther. Apher. Dial. (2003) 7:334-340.
   PubMed Web of Science ®Google Scholar
• SANIABADI AR, HANAI H, SUZUKI Y, BJARNASON I, LOFBERG R: Adacolumn for selective leukocytapheresis as a non-pharmacological treatment for patients with disorders of the immune system: an adjunct or an alternative to drug therapy?. J. Clin. Apher. (2005) 20:171-184.
   Google Scholar
• SHIMOYAMA T, SAWADA K, TANAKA T et al.: Granulocyte and monocyte apheresis with the G-1 column in the treatment of patients with active ulcerative colitis. Jpn. J. Apher. (1999) 18:117-131.
   Google Scholar
• STACK WA, LONG RG, HAWKEY CJ: Short and long-term outcome of patients treated with cyclosporin for severe acute ulcerative colitis. Aliment. Pharmacol. Ther. (1998) 12:973-978.
   PubMed Web of Science ®Google Scholar
• KANKE K, NAKANO M, HIRAISHI H, TERANO A: Evaluation of granulocyte/monocyte apheresis therapy for active ulcerative colitis. Dig. Liv. Dis. (2004) 36:512-518.
   Google Scholar
• NAGANUMA M, FUNAKOSHI S, SAKURABA A et al.: Granulocytapheresis is useful as an alternative therapy in patients with steroid-refractory or -dependent ulcerative colitis. Inflamm. Bowel Dis. (2004) 10:251-257.
   PubMed Web of Science ®Google Scholar
• YAMAMOTO T, UMEGAE S, KITAGAWA T, YASUDA Y, YAMADA Y, TAKAHASHI D: Granulocyte and monocyte adsorptive apheresis in the treatment of active distal ulcerative colitis: a prospective, pilot study. Aliment. Pharmacol. Ther. (2004) 20:783-792.
   PubMed Web of Science ®Google Scholar
• PREMCHAND P, TAKEUCHI K, BJARNASON I: Granulocyte, macrophage, monocyte apheresis for refractory ulcerative proctitis. Eur. J. Gastroenterol. Hepatol. (2004) 16:943-945.
   PubMed Web of Science ®Google Scholar
• DOMENECH E, HINOJOSA J, ESTEVE-COMAS M, GASSULL A: Spanish Group for the Study of Crohn’s Disease and Ulcerative Colitis (GETECCU). Granulocyteaphaeresis in steroid-dependent inflammatory bowel disease: a prospective, open, pilot study. Aliment. Pharmacol. Ther. (2004) 20:1347-1352.
   PubMed Web of Science ®Google Scholar
• SUZUKI Y, YOSHIMURA N, SANIABADI AR, SAITO Y: Selective neutrophil and monocyte adsorptive apheresis as a first line treatment for steroid naïve patients with active ulcerative colitis: a prospective uncontrolled study. Dig. Dis. Sci. (2004) 49:565-571.
   PubMed Web of Science ®Google Scholar
• COHEN RD: Treating ulcerative colitis without medications – ‘Look Mom, No Drugs!’ Gastroenterology (2005) 128:235-236:
   PubMedGoogle Scholar
• MAIDEN L, BAUR R, TAKEUCHI K et al.: Adacolumn apheresis reduces relapse rates in patients at significant risk of clinical relapse (Abstr). Gut (2005) 54:A57.
   Google Scholar
• MATSUI T, NISHIMURA T, MATAKE H, OHTA T, SAKURAI T, YAO T: Granulocytapheresis for Crohn’s disease: a report on seven refractory patients. Am. J. Gastroenterol. (2003) 98:511-512.
   PubMed Web of Science ®Google Scholar
• FUKUDA Y, MATSUI T, SUZUKI Y, KANKE K, HIBI T: granulocyte and monocyte apheresis for refractory Crohn’s disease: an open multicenter prospective study. J. Gastroenterol. (2004) 39:1158-1164.
   PubMed Web of Science ®Google Scholar
• MURATOV V, LUNDAHL J, ULFGREN AK et al.: Downregulation of interferon- parallels clinical response to selective leukocyte apheresis in patients with inflammatory bowel disease. A 12-month follow-up study. Int. J. Colorectal Dis. (2006) (In Press).
   PubMedGoogle Scholar
• HANAI H, WATANABE F, SANIABADI A et al.: Correlation of serum soluble TNF-alpha receptors I and II levels with disease activity in patients with ulcerative colitis. Am. J. Gastroenterol. (2004) 99:1532-1538.
   PubMed Web of Science ®Google Scholar
• MOHLER KM, TORRANCE DS, SMITH GA, WIDMER MB: Soluble tumour necrosis factor (TNF) receptors are effective therapeutic agents in lethal endotoximia and function simultaneously as both TNF carriers and TNF antagonists. J. Immunol. (1993) 151:1548-1561.
   Google Scholar
• KASHIWAGI N, HIRATA I, KASUKAWA R: A role for granulocyte and monocyte apheresis in the treatment of rheumatoid arthritis. Ther. Apher. (1998) 2:134-141
   PubMedGoogle Scholar
• KASHIWAGI N, SANIABADI A, SHIMOYAMA T et al.: Immunomodulatory effects of granulocyte and monocyte adsorption apheresis as a treatment for patients with ulcerative colitis. Dig. Dig. Sci. (2002) 47:1334-1341.
   PubMed Web of Science ®Google Scholar
• BISWAS P, MANTELLI B, HASSON H, SANIABADI A, LAZZARIN A, BERETTA A: In vivo modulation of leukocyte trafficking receptor following therapeutic purging of myeloid cells: implications for treatment of HIV infection and other immune disorders. Clin. Immunol. (2003) 109:355-358.
   PubMed Web of Science ®Google Scholar
• TAKEDA Y, SHIOBARA N, SANIABADI AR, ADACHI M, HIRAISHI K: Adhesion dependent release of hepatocyte growth factor and interleukin-1 receptor antagonist from human blood granulocytes and monocytes: evidence for the involvement of plasma IgG, complement C3 and β2 integrin. Inflamm. Res. (2004) 53:277-283.
   Google Scholar
• TAHARA Y, IDO A, YAMAMOTO S, MIYATA Y, UTO H, HORI T: Hepatocyte growth factor facilitates colonic mucosal repair in experimental ulcerative colitis in rats. J. Pharmacol. Exp. Ther. (2003) 307:146-151.
   PubMed Web of Science ®Google Scholar
• SAWADA K, MUTO T, SHIMOYAMA T et al.: Multicenter randomized controlled trial for the treatment of ulcerative colitis with a leukocytapheresis colum. Curr. Pharm. Des. (1997) 9:307-321.
   Google Scholar
• SHIROKAZE J: Leukocytapheresis using a leukocyte removal filter. Ther. Apher. (2002) 6:261-266.
   Google Scholar
• SAWADA K, OHNISHI K, FUKUI S: Leukocytapheresis therapy performed with leukocyte removal filter for inflammatory bowel disease. J. Gastroenterol. (1995) 30:322-329.
   PubMed Web of Science ®Google Scholar
• SAWADA K, KUSUGAMI K, SUZUKI Y et al.: Leukocytapheresis in ulcerative colitis: results of a multicenter double-blind prospective case-control study with sham apheresis as placebo treatment. Am. J. Gastroenterol. (2005) 100:1362-1369.
   PubMed Web of Science ®Google Scholar
• SAWADA K, EGASHIRA A, OHNISHI K, FUKUNAGA K, KASUKA T, SHIMOYAMA T: Leukocytapheresis (LCAP) for management of fulminant ulcerative colitis with toxic megacolon. Dig. Dis. Sci. (2005) 50:767-773.
   PubMed Web of Science ®Google Scholar
• SAWADA K, MUTO T, SHIMOYAMA T: Leukocytapheresis with leukocyte removal filter as new therapy for ulcerative colitis. Ther. Apher. (1997) 1:207-211.
   PubMedGoogle Scholar
• YAMAJI K, YANG K, TSUDA H, HASHIMOTO H: Fluctuations in the peripheral blood leukocyte and platelet counts in leukocytapheresis in healthy volunteers. Ther. Apher. (2002) 6:402-412.
   PubMedGoogle Scholar
• SHIBATA H, KURIYAMA T, YAMAWAKI N: Cellsorba. Ther. Apher. Dial. (2003) 7:44-47.
   PubMed Web of Science ®Google Scholar
• KING C, ILIC A, KOELSCH K, SARVETNICK N: Homeostatic expansion of T cells during immune insufficiency generates autoimmunity. Cell (2004) 117:265-277.
   PubMed Web of Science ®Google Scholar
• SLEASMAN JW: The association between immunodeficiency and the development of autoimmune disease. Adv. Dent. Res. (1996) 10:57-61.
   PubMedGoogle Scholar
• NOGUCHI M, HIWATASHI N, HAYAKAWA T, TOYOTA T: Leukocyte removal filter-passed lymphocytes produce large amounts of interleukin-4 in immunotherapy for inflammatory bowel disease: role of bystander suppression. Ther. Apher. (1998) 2:109-114.
   PubMedGoogle Scholar
• ANDOH A, TSUJIKAWA T, INATOMI O et al.: Leukocytaoheresis therapy modulates circulating T cell subsets in patients with ulcerative colitis. Ther. Apher. Dial. (2005) 9:270-279.
   PubMed Web of Science ®Google Scholar
• BRESNIHAN B, CUNNANE G: Infection complications associated with the use of biologic agents. Rheum. Dis. Clin. North Am. (2003) 29:185-202.
   Google Scholar
• EGAN LJ, SANDBORN WJ: Advances in the treatment of Crohn’s disease. Gastroenterology (2004) 126:1574-1581.
   PubMed Web of Science ®Google Scholar
• SHAND A, FORBES A: Potential therapeutic role for cytokine or adhesion molecule manipulation in Crohn’s disease: in the shadow of infliximab? Int. J. Colorectal Dis. (2003) 18:1-11.
   Google Scholar
• CAMPBELL DJ, DEBES GF, JOHNSTON B, WILSON E, BUTCHER EC: Targeting T cell responses by selective chemokine receptor expression. Semin. Immunol. (2003) 15:277-286.
   PubMed Web of Science ®Google Scholar
• MACKAY CR, MARSTON WL, DUDLER L: Naïve and memory T cells show distinct pathways of lymphocyte recirculation. J. Exp. Med. (1990) 171:801-817.
   PubMed Web of Science ®Google Scholar
• OLSZEWSKI WL: The lymphatic system in body homeostasis: physiological conditions. Lymphat. Res. Biol. (2003) 1:11-21.
   PubMedGoogle Scholar
• BROMLEY SK, THOMAS SY, LUSTER AD: Chemokine receptor CCR7 guides T cell exit from peripheral tissues and entry into afferent lymphatics. Nat. Immunol. (2005) 6:895-901.
   PubMed Web of Science ®Google Scholar
• DEBES GF, ARNOLD CN, YOUNG AJ et al.: Chemokine receptor CCR7 required for T lymphocyte exit from peripheral tissues. Nat. Immunol. (2005) 6:889-894.
   PubMed Web of Science ®Google Scholar
• KLONOWSKI KD: Dynamics of blood-borne CD8 memory T cell migration in vivo. Immunity (2004) 20:551-562.
   PubMed Web of Science ®Google Scholar
• LEE A, WHYTE M, HASLETT C: Inhibition of apoptosis and prolongation of neutrophil functional longevity by inflammatory mediators. J. Leukoc. Biol. (1993) 54:283-288.
   PubMed Web of Science ®Google Scholar